Diabetic dyslipidemia and cardiovascular risk

Current Diabetes Reports

Volumn 8, Issue 6, 2008, Pages 421-423

  Eckel, Robert H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 63149154320     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0072-4     Document Type: Note

References (21)

1. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM: Comparability of cause of death between ICD-9 and ICD-10: Preliminary estimates. Natl Vital Stat Rep 2001, 49: 1-32.
2. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365: 1415-1428.
3. Wadwa RP, Kinney GL, Maahs DM, et al.: Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 2005, 28: 1051-1056.
4. Miettinen TA, Gylling H, Tuominen J, et al.: Low synthesis and high absorption of cholesterol characterize type 1 diabetes. Diabetes Care 2004, 27: 53-58.
5. Forrest KY, Becker DJ, Kuller LH, et al.: Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 2000, 148: 159-169.
6. Dabelea D, Kinney G, Snell-Bergeon JK, et al.: Effect of type 1 diabetes on the gender difference in coronary artery calcification: A role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003, 52: 2833-2839.
7. Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008, 371: 1800-1809.
8. Lee SJ, Campos H, Moye LA, Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003, 23: 853-858.
9. Eto M, Watanabe K, Sato T, Makino I: Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989, 69: 1207-1212.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285: 2486-2497.
11. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735-2752.
12. Liu J, Sempos C, Donahue RP, et al.: Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005, 28: 1916-1921.
13. Lu W, Resnick HE, Jablonski KA, et al.: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care 2003, 26: 16-23.
14. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ 2006, 332: 1115-1124.
15. Steinmetz A: Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes 2003, 111: 239-245.
16. Koppes LL, Dekker JM, Hendriks HF, et al.: Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients. Diabetologia 2006, 49: 648-652.
17. Buse JB, Bigger JT, Byington RP, et al.: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol 2007, 99: 21i-33i.
18. Reasner CA: What is the most effective strategy for managing diabetic dyslipidaemia? Atheroscler Suppl 2005, 6: 21-27.
19. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366: 1279-1289.
20. Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358: 1431-1443.
21. Staels B, Kuipers F: Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007, 67: 1383-1392.